Literature DB >> 33548914

Acthar® Gel (repository corticotropin injection) dose-response relationships in an animal model of epileptic spasms.

John T Le1, James D Frost2, John W Swann3.   

Abstract

Studies were undertaken to evaluate the effectiveness of Acthar® Gel (repository corticotropin injection [RCI]) in the tetrodotoxin (TTX) model of early-life-induced epileptic spasms. Repository corticotropin injection (RCI) is widely used in the United States to treat infantile spasms. A major component of RCI is N25 deamidated ACTH. Additionally, we hoped to provide some insight into the possible role circulating corticosteroids play in spasm cessation by comparing the RCI dose-response relationships for spasm suppression to RCI-induced corticosterone release from the adrenal gland. Spasms were induced by chronic TTX infusion into the neocortex beginning on postnatal day 11. Repository corticotropin injection (RCI) dosages were between 8 and 32 IU/kg/day. Drug titration protocols were used, and comparisons were made to injections of a vehicle gel. Video/EEG recordings (24/7) monitored the drug's effects continuously for up to 2 months. Tetrodotoxin (TTX)-infused control rats were monitored for the same period of time. In separate experiments, the same dosages of RCI were given to rats and 1 h later plasma was collected and assayed for corticosterone. A parallel study compared the effects of 1-day and 10-day RCI treatments on circulating corticosterone. Results showed that RCI was ineffective at dosages of 8, 12, and 16 IU/kg/day but eliminated spasms in 66% of animals treated with 24 or 32 IU/kg/day. Treating animals with 32 IU/kg/day alone produced the same degree of spasms suppression as observed during the titration protocols. In rats that had hypsarrhythmia-like activity, RCI eliminated this abnormal interictal EEG pattern in all rats that became seizure-free. In terms of plasma corticosterone, 1- and 10-day treatments with RCI produced similar increases in this hormone and the levels increased linearly with increasing dosages of RCI. This stood in sharp contrast to the sigmoid-like dose-response curve for decreases in spasm counts. Our results further validate the TTX model as relevant for the study of infantile spasms. The model should be useful for investigating how RCI acts to eliminate seizures and hypsarrhythmia. Dose-response results suggest that either very high concentrations of circulating corticosteroids are required to abolish spasms or RCI acts through a different mechanism.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ACTH; Corticosterone; Corticotropin; Hypsarrhythmia; Infantile spasms; Video/EEG; West syndrome

Mesh:

Substances:

Year:  2021        PMID: 33548914      PMCID: PMC7940582          DOI: 10.1016/j.yebeh.2021.107786

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   3.337


  54 in total

1.  APC conditional knock-out mouse is a model of infantile spasms with elevated neuronal β-catenin levels, neonatal spasms, and chronic seizures.

Authors:  Antonella Pirone; Jonathan Alexander; Lauren A Lau; David Hampton; Andrew Zayachkivsky; Amy Yee; Audrey Yee; Michele H Jacob; Chris G Dulla
Journal:  Neurobiol Dis       Date:  2016-11-13       Impact factor: 5.996

2.  Randomized, Single-Blind, Parallel Clinical Trial on Efficacy of Oral Prednisolone Versus Intramuscular Corticotropin: A 12-Month Assessment of Spasm Control in West Syndrome.

Authors:  Jithangi Wanigasinghe; Carukshi Arambepola; Shalini Sri Ranganathan; Samanmali Sumanasena
Journal:  Pediatr Neurol       Date:  2017-08-14       Impact factor: 3.372

3.  Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.

Authors:  C Y Go; M T Mackay; S K Weiss; D Stephens; T Adams-Webber; S Ashwal; O C Snead
Journal:  Neurology       Date:  2012-06-12       Impact factor: 9.910

4.  Vigabatrin therapy implicates neocortical high frequency oscillations in an animal model of infantile spasms.

Authors:  James D Frost; John T Le; Chong L Lee; Carlos Ballester-Rosado; Richard A Hrachovy; John W Swann
Journal:  Neurobiol Dis       Date:  2015-05-27       Impact factor: 5.996

5.  Hypsarrhythmia: variations on the theme.

Authors:  R A Hrachovy; J D Frost; P Kellaway
Journal:  Epilepsia       Date:  1984-06       Impact factor: 5.864

6.  Infantile spasms in remission may reemerge as intractable epileptic spasms.

Authors:  Peter Camfield; Carol Camfield; Anne Lortie; Husam Darwish
Journal:  Epilepsia       Date:  2003-12       Impact factor: 5.864

7.  Dose translation from animal to human studies revisited.

Authors:  Shannon Reagan-Shaw; Minakshi Nihal; Nihal Ahmad
Journal:  FASEB J       Date:  2007-10-17       Impact factor: 5.191

8.  High-dose oral prednisolone for infantile spasms: an effective and less expensive alternative to ACTH.

Authors:  Eric H Kossoff; Adam L Hartman; James E Rubenstein; Eileen P G Vining
Journal:  Epilepsy Behav       Date:  2009-02-04       Impact factor: 2.937

9.  A triplet repeat expansion genetic mouse model of infantile spasms syndrome, Arx(GCG)10+7, with interneuronopathy, spasms in infancy, persistent seizures, and adult cognitive and behavioral impairment.

Authors:  Maureen G Price; Jong W Yoo; Daniel L Burgess; Fang Deng; Richard A Hrachovy; James D Frost; Jeffrey L Noebels
Journal:  J Neurosci       Date:  2009-07-08       Impact factor: 6.167

10.  Clinical and electrographic features of epileptic spasms persisting beyond the second year of life.

Authors:  Márcio A Sotero de Menezes; Jong M Rho
Journal:  Epilepsia       Date:  2002-06       Impact factor: 5.864

View more
  1 in total

1.  A Role for Insulin-like Growth Factor 1 in the Generation of Epileptic Spasms in a murine model.

Authors:  Carlos J Ballester-Rosado; John T Le; Trang T Lam; Carrie A Mohila; Sandi Lam; Anne E Anderson; James D Frost; John W Swann
Journal:  Ann Neurol       Date:  2022-05-10       Impact factor: 11.274

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.